375 related articles for article (PubMed ID: 35346089)
1. Effect of gender, age and vaccine on reactogenicity and incapacity to work after COVID-19 vaccination: a survey among health care workers.
Nachtigall I; Bonsignore M; Hohenstein S; Bollmann A; Günther R; Kodde C; Englisch M; Ahmad-Nejad P; Schröder A; Glenz C; Kuhlen R; Thürmann P; Meier-Hellmann A
BMC Infect Dis; 2022 Mar; 22(1):291. PubMed ID: 35346089
[TBL] [Abstract][Full Text] [Related]
2. Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study.
Warkentin L; Werner F; Zeschick N; Kühlein T; Steininger P; Überla K; Kaiser I; Sebastião M; Hueber S
BMC Med; 2023 Jun; 21(1):218. PubMed ID: 37340463
[TBL] [Abstract][Full Text] [Related]
3. Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study.
Warkentin L; Zeschick N; Kühlein T; Steininger P; Überla K; Kaiser I; Gall C; Sebastião M; Hueber S
BMC Infect Dis; 2022 May; 22(1):504. PubMed ID: 35641934
[TBL] [Abstract][Full Text] [Related]
4. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
5. Homologous COVID-19 BNT162b2 mRNA Vaccination at a German Tertiary Care University Hospital: A Survey-Based Analysis of Reactogenicity, Safety, and Inability to Work among Healthcare Workers.
Niekrens V; Esse J; Held J; Knobloch CS; Steininger P; Kunz B; Seggewies C; Bogdan C
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632406
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study.
Werner F; Zeschick N; Kühlein T; Steininger P; Überla K; Kaiser I; Sebastião M; Hueber S; Warkentin L
BMC Med; 2023 Sep; 21(1):358. PubMed ID: 37726711
[TBL] [Abstract][Full Text] [Related]
7. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: a prospective observational study.
Naito T; Tsuchida N; Kusunoki S; Kaneko Y; Tobita M; Hori S; Ito S
Expert Rev Vaccines; 2022 Sep; 21(9):1319-1329. PubMed ID: 35763290
[TBL] [Abstract][Full Text] [Related]
8. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
Baldolli A; Fournier A; Verdon R; Michon J
Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
[TBL] [Abstract][Full Text] [Related]
9. Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
Cheng A; Hsieh MJ; Chang SY; Ieong SM; Cheng CY; Sheng WH; Chang SC
J Formos Med Assoc; 2023 May; 122(5):384-392. PubMed ID: 36564299
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis.
Briggs FBS; Mateen FJ; Schmidt H; Currie KM; Siefers HM; Crouthamel S; Bebo BF; Fiol J; Racke MK; O'Connor KC; Kolaczkowski LG; Klein P; Loud S; McBurney RN
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753828
[TBL] [Abstract][Full Text] [Related]
11. Reactogenicity of the BNT162b2 mRNA vaccine (Pfizer-BioNTech) against COVID-19 in workers of a tertiary hospital.
Palomo-Palomo C; Guerra-Estévez D; Parrado-González A; Estaire-Gutiérrez J; Reyes-Malia M; Romero-Alonso MM
Farm Hosp; 2022 Mar; 46(3):152-156. PubMed ID: 36183208
[TBL] [Abstract][Full Text] [Related]
12. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
13. Vaccine Side Effects in Health Care Workers after Vaccination against SARS-CoV-2: Data from TüSeRe:exact Study.
Bareiß A; Uzun G; Mikus M; Becker M; Althaus K; Schneiderhan-Marra N; Fürstberger A; Schwab JD; Kestler HA; Holderried M; Martus P; Schenke-Layland K; Bakchoul T
Viruses; 2022 Dec; 15(1):. PubMed ID: 36680106
[TBL] [Abstract][Full Text] [Related]
14. Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines-Early experience with vaccine rollout in a multi-site healthcare system.
Al-Obaydi S; Hennrikus E; Mohammad N; Lehman EB; Thakur A; Al-Shaikhly T
PLoS One; 2022; 17(8):e0272691. PubMed ID: 35930586
[TBL] [Abstract][Full Text] [Related]
15. Reactogenicity of Simultaneous COVID-19 mRNA Booster and Influenza Vaccination in the US.
Hause AM; Zhang B; Yue X; Marquez P; Myers TR; Parker C; Gee J; Su J; Shimabukuro TT; Shay DK
JAMA Netw Open; 2022 Jul; 5(7):e2222241. PubMed ID: 35838667
[TBL] [Abstract][Full Text] [Related]
16. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
[TBL] [Abstract][Full Text] [Related]
17. Humoral immune response after different SARS-CoV-2 vaccination regimens.
Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
[TBL] [Abstract][Full Text] [Related]
18. Differences by sex in IgG levels following infant and childhood vaccinations: An individual participant data meta-analysis of vaccination studies.
Boef AGC; van der Klis FRM; Berbers GAM; Buisman AM; Sanders EAM; Kemmeren JM; van der Ende A; de Melker HE; Rots NY; Knol MJ
Vaccine; 2018 Jan; 36(3):400-407. PubMed ID: 29223483
[TBL] [Abstract][Full Text] [Related]
19. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Adults - United States, September 22, 2021-February 6, 2022.
Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Blanc PG; Gwira Baumblatt JA; Woo EJ; Gee J; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):249-254. PubMed ID: 35176008
[TBL] [Abstract][Full Text] [Related]
20. Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination.
Chrissian AA; Oyoyo UE; Patel P; Lawrence Beeson W; Loo LK; Tavakoli S; Dubov A
Vaccine; 2022 May; 40(23):3174-3181. PubMed ID: 35465979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
